Selected research
Market Analysis & Forecast
Global NGS for Multi-cancer Early Screening Market Analysis and Forecast 2026-2032
Market perspective
The global NGS for Multi-cancer Early Screening market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for NGS for Multi-cancer Early Screening is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for NGS for Multi-cancer Early Screening is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for NGS for Multi-cancer Early Screening is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for NGS for Multi-cancer Early Screening is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of NGS for Multi-cancer Early Screening include Guardant Health, Exact Sciences, Freenome, Epiginomics AG, Bio-techne, ThriveEarlier Detection, GRAIL, Inc., CellMax life and Berry Genomics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for NGS for Multi-cancer Early Screening, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of NGS for Multi-cancer Early Screening, also provides the revenue of main regions and countries. Of the upcoming market potential for NGS for Multi-cancer Early Screening, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the NGS for Multi-cancer Early Screening revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global NGS for Multi-cancer Early Screening market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for NGS for Multi-cancer Early Screening revenue, projected growth trends, production technology, application and end-user industry.
NGS for Multi-cancer Early Screening Segment by Company
Guardant Health
Exact Sciences
Freenome
Epiginomics AG
Bio-techne
ThriveEarlier Detection
GRAIL, Inc.
CellMax life
Berry Genomics
Singlera Genomics
Geneseeq
Burning Rock Biotech Limited
New Horizon Health Limited
NGS for Multi-cancer Early Screening Segment by Type
ctDNA Gene Mutation Detection
cfDNA Methylation Sequencing
NGS for Multi-cancer Early Screening Segment by Application
Medical Institutions
Physical Examination Centers
NGS for Multi-cancer Early Screening Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NGS for Multi-cancer Early Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of NGS for Multi-cancer Early Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NGS for Multi-cancer Early Screening.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of NGS for Multi-cancer Early Screening in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of NGS for Multi-cancer Early Screening company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, NGS for Multi-cancer Early Screening revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- ctDNA Gene Mutation Detection
- cfDNA Methylation Sequencing
Applications
- Medical Institutions
- Physical Examination Centers
Companies covered
- Guardant Health
- Exact Sciences
- Freenome
- Epiginomics AG
- Bio-techne
- ThriveEarlier Detection
- GRAIL, Inc.
- CellMax life
- Berry Genomics
- Singlera Genomics
- Geneseeq
- Burning Rock Biotech Limited
- New Horizon Health Limited
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 NGS for Multi-cancer Early Screening Market by Type
- 1.2.1 Global NGS for Multi-cancer Early Screening Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 ctDNA Gene Mutation Detection
- 1.2.3 cfDNA Methylation Sequencing
- 1.3 NGS for Multi-cancer Early Screening Market by Application
- 1.3.1 Global NGS for Multi-cancer Early Screening Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Medical Institutions
- 1.3.3 Physical Examination Centers
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 NGS for Multi-cancer Early Screening Market Dynamics
- 2.1 NGS for Multi-cancer Early Screening Industry Trends
- 2.2 NGS for Multi-cancer Early Screening Industry Drivers
- 2.3 NGS for Multi-cancer Early Screening Industry Opportunities and Challenges
- 2.4 NGS for Multi-cancer Early Screening Industry Restraints
3 Global Growth Perspective
- 3.1 Global NGS for Multi-cancer Early Screening Market Perspective (2021-2032)
- 3.2 Global NGS for Multi-cancer Early Screening Growth Trends by Region
- 3.2.1 Global NGS for Multi-cancer Early Screening Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global NGS for Multi-cancer Early Screening Market Size by Region (2021-2026)
- 3.2.3 Global NGS for Multi-cancer Early Screening Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global NGS for Multi-cancer Early Screening Revenue by Players
- 4.1.1 Global NGS for Multi-cancer Early Screening Revenue by Players (2021-2026)
- 4.1.2 Global NGS for Multi-cancer Early Screening Revenue Market Share by Players (2021-2026)
- 4.1.3 Global NGS for Multi-cancer Early Screening Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global NGS for Multi-cancer Early Screening Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global NGS for Multi-cancer Early Screening Key Players Headquarters & Area Served
- 4.4 Global NGS for Multi-cancer Early Screening Players, Product Type & Application
- 4.5 Global NGS for Multi-cancer Early Screening Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global NGS for Multi-cancer Early Screening Market CR5 and HHI
- 4.6.3 2025 NGS for Multi-cancer Early Screening Tier 1, Tier 2, and Tier 3
5 NGS for Multi-cancer Early Screening Market Size by Type
- 5.1 Global NGS for Multi-cancer Early Screening Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global NGS for Multi-cancer Early Screening Revenue by Type (2021-2032)
- 5.3 Global NGS for Multi-cancer Early Screening Revenue Market Share by Type (2021-2032)
6 NGS for Multi-cancer Early Screening Market Size by Application
- 6.1 Global NGS for Multi-cancer Early Screening Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global NGS for Multi-cancer Early Screening Revenue by Application (2021-2032)
- 6.3 Global NGS for Multi-cancer Early Screening Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Guardant Health
- 7.1.1 Guardant Health Company Information
- 7.1.2 Guardant Health Business Overview
- 7.1.3 Guardant Health NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
- 7.1.4 Guardant Health NGS for Multi-cancer Early Screening Product Portfolio
- 7.1.5 Guardant Health Recent Developments
- 7.2 Exact Sciences
- 7.2.1 Exact Sciences Company Information
- 7.2.2 Exact Sciences Business Overview
- 7.2.3 Exact Sciences NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
- 7.2.4 Exact Sciences NGS for Multi-cancer Early Screening Product Portfolio
- 7.2.5 Exact Sciences Recent Developments
- 7.3 Freenome
- 7.3.1 Freenome Company Information
- 7.3.2 Freenome Business Overview
- 7.3.3 Freenome NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
- 7.3.4 Freenome NGS for Multi-cancer Early Screening Product Portfolio
- 7.3.5 Freenome Recent Developments
- 7.4 Epiginomics AG
- 7.4.1 Epiginomics AG Company Information
- 7.4.2 Epiginomics AG Business Overview
- 7.4.3 Epiginomics AG NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
- 7.4.4 Epiginomics AG NGS for Multi-cancer Early Screening Product Portfolio
- 7.4.5 Epiginomics AG Recent Developments
- 7.5 Bio-techne
- 7.5.1 Bio-techne Company Information
- 7.5.2 Bio-techne Business Overview
- 7.5.3 Bio-techne NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
- 7.5.4 Bio-techne NGS for Multi-cancer Early Screening Product Portfolio
- 7.5.5 Bio-techne Recent Developments
- 7.6 ThriveEarlier Detection
- 7.6.1 ThriveEarlier Detection Company Information
- 7.6.2 ThriveEarlier Detection Business Overview
- 7.6.3 ThriveEarlier Detection NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
- 7.6.4 ThriveEarlier Detection NGS for Multi-cancer Early Screening Product Portfolio
- 7.6.5 ThriveEarlier Detection Recent Developments
- 7.7 GRAIL, Inc.
- 7.7.1 GRAIL, Inc. Company Information
- 7.7.2 GRAIL, Inc. Business Overview
- 7.7.3 GRAIL, Inc. NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
- 7.7.4 GRAIL, Inc. NGS for Multi-cancer Early Screening Product Portfolio
- 7.7.5 GRAIL, Inc. Recent Developments
- 7.8 CellMax life
- 7.8.1 CellMax life Company Information
- 7.8.2 CellMax life Business Overview
- 7.8.3 CellMax life NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
- 7.8.4 CellMax life NGS for Multi-cancer Early Screening Product Portfolio
- 7.8.5 CellMax life Recent Developments
- 7.9 Berry Genomics
- 7.9.1 Berry Genomics Company Information
- 7.9.2 Berry Genomics Business Overview
- 7.9.3 Berry Genomics NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
- 7.9.4 Berry Genomics NGS for Multi-cancer Early Screening Product Portfolio
- 7.9.5 Berry Genomics Recent Developments
- 7.10 Singlera Genomics
- 7.10.1 Singlera Genomics Company Information
- 7.10.2 Singlera Genomics Business Overview
- 7.10.3 Singlera Genomics NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
- 7.10.4 Singlera Genomics NGS for Multi-cancer Early Screening Product Portfolio
- 7.10.5 Singlera Genomics Recent Developments
- 7.11 Geneseeq
- 7.11.1 Geneseeq Company Information
- 7.11.2 Geneseeq Business Overview
- 7.11.3 Geneseeq NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
- 7.11.4 Geneseeq NGS for Multi-cancer Early Screening Product Portfolio
- 7.11.5 Geneseeq Recent Developments
- 7.12 Burning Rock Biotech Limited
- 7.12.1 Burning Rock Biotech Limited Company Information
- 7.12.2 Burning Rock Biotech Limited Business Overview
- 7.12.3 Burning Rock Biotech Limited NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
- 7.12.4 Burning Rock Biotech Limited NGS for Multi-cancer Early Screening Product Portfolio
- 7.12.5 Burning Rock Biotech Limited Recent Developments
- 7.13 New Horizon Health Limited
- 7.13.1 New Horizon Health Limited Company Information
- 7.13.2 New Horizon Health Limited Business Overview
- 7.13.3 New Horizon Health Limited NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
- 7.13.4 New Horizon Health Limited NGS for Multi-cancer Early Screening Product Portfolio
- 7.13.5 New Horizon Health Limited Recent Developments
8 North America
- 8.1 North America NGS for Multi-cancer Early Screening Revenue (2021-2032)
- 8.2 North America NGS for Multi-cancer Early Screening Revenue by Type (2021-2032)
- 8.2.1 North America NGS for Multi-cancer Early Screening Revenue by Type (2021-2026)
- 8.2.2 North America NGS for Multi-cancer Early Screening Revenue by Type (2027-2032)
- 8.3 North America NGS for Multi-cancer Early Screening Revenue Share by Type (2021-2032)
- 8.4 North America NGS for Multi-cancer Early Screening Revenue by Application (2021-2032)
- 8.4.1 North America NGS for Multi-cancer Early Screening Revenue by Application (2021-2026)
- 8.4.2 North America NGS for Multi-cancer Early Screening Revenue by Application (2027-2032)
- 8.5 North America NGS for Multi-cancer Early Screening Revenue Share by Application (2021-2032)
- 8.6 North America NGS for Multi-cancer Early Screening Revenue by Country
- 8.6.1 North America NGS for Multi-cancer Early Screening Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America NGS for Multi-cancer Early Screening Revenue by Country (2021-2026)
- 8.6.3 North America NGS for Multi-cancer Early Screening Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe NGS for Multi-cancer Early Screening Revenue (2021-2032)
- 9.2 Europe NGS for Multi-cancer Early Screening Revenue by Type (2021-2032)
- 9.2.1 Europe NGS for Multi-cancer Early Screening Revenue by Type (2021-2026)
- 9.2.2 Europe NGS for Multi-cancer Early Screening Revenue by Type (2027-2032)
- 9.3 Europe NGS for Multi-cancer Early Screening Revenue Share by Type (2021-2032)
- 9.4 Europe NGS for Multi-cancer Early Screening Revenue by Application (2021-2032)
- 9.4.1 Europe NGS for Multi-cancer Early Screening Revenue by Application (2021-2026)
- 9.4.2 Europe NGS for Multi-cancer Early Screening Revenue by Application (2027-2032)
- 9.5 Europe NGS for Multi-cancer Early Screening Revenue Share by Application (2021-2032)
- 9.6 Europe NGS for Multi-cancer Early Screening Revenue by Country
- 9.6.1 Europe NGS for Multi-cancer Early Screening Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe NGS for Multi-cancer Early Screening Revenue by Country (2021-2026)
- 9.6.3 Europe NGS for Multi-cancer Early Screening Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China NGS for Multi-cancer Early Screening Revenue (2021-2032)
- 10.2 China NGS for Multi-cancer Early Screening Revenue by Type (2021-2032)
- 10.2.1 China NGS for Multi-cancer Early Screening Revenue by Type (2021-2026)
- 10.2.2 China NGS for Multi-cancer Early Screening Revenue by Type (2027-2032)
- 10.3 China NGS for Multi-cancer Early Screening Revenue Share by Type (2021-2032)
- 10.4 China NGS for Multi-cancer Early Screening Revenue by Application (2021-2032)
- 10.4.1 China NGS for Multi-cancer Early Screening Revenue by Application (2021-2026)
- 10.4.2 China NGS for Multi-cancer Early Screening Revenue by Application (2027-2032)
- 10.5 China NGS for Multi-cancer Early Screening Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia NGS for Multi-cancer Early Screening Revenue (2021-2032)
- 11.2 Asia NGS for Multi-cancer Early Screening Revenue by Type (2021-2032)
- 11.2.1 Asia NGS for Multi-cancer Early Screening Revenue by Type (2021-2026)
- 11.2.2 Asia NGS for Multi-cancer Early Screening Revenue by Type (2027-2032)
- 11.3 Asia NGS for Multi-cancer Early Screening Revenue Share by Type (2021-2032)
- 11.4 Asia NGS for Multi-cancer Early Screening Revenue by Application (2021-2032)
- 11.4.1 Asia NGS for Multi-cancer Early Screening Revenue by Application (2021-2026)
- 11.4.2 Asia NGS for Multi-cancer Early Screening Revenue by Application (2027-2032)
- 11.5 Asia NGS for Multi-cancer Early Screening Revenue Share by Application (2021-2032)
- 11.6 Asia NGS for Multi-cancer Early Screening Revenue by Country
- 11.6.1 Asia NGS for Multi-cancer Early Screening Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia NGS for Multi-cancer Early Screening Revenue by Country (2021-2026)
- 11.6.3 Asia NGS for Multi-cancer Early Screening Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA NGS for Multi-cancer Early Screening Revenue (2021-2032)
- 12.2 SAMEA NGS for Multi-cancer Early Screening Revenue by Type (2021-2032)
- 12.2.1 SAMEA NGS for Multi-cancer Early Screening Revenue by Type (2021-2026)
- 12.2.2 SAMEA NGS for Multi-cancer Early Screening Revenue by Type (2027-2032)
- 12.3 SAMEA NGS for Multi-cancer Early Screening Revenue Share by Type (2021-2032)
- 12.4 SAMEA NGS for Multi-cancer Early Screening Revenue by Application (2021-2032)
- 12.4.1 SAMEA NGS for Multi-cancer Early Screening Revenue by Application (2021-2026)
- 12.4.2 SAMEA NGS for Multi-cancer Early Screening Revenue by Application (2027-2032)
- 12.5 SAMEA NGS for Multi-cancer Early Screening Revenue Share by Application (2021-2032)
- 12.6 SAMEA NGS for Multi-cancer Early Screening Revenue by Country
- 12.6.1 SAMEA NGS for Multi-cancer Early Screening Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA NGS for Multi-cancer Early Screening Revenue by Country (2021-2026)
- 12.6.3 SAMEA NGS for Multi-cancer Early Screening Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst